Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CANAGLIFLOZIN

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (A10B, A10BK) — coverage varies; not interchangeable

  • Dapagliflozin (Forxiga): general benefit
  • Empagliflozin (Jardiance): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin + metformin (Synjardy): general benefit
  • Gliclazide (Diamicron MR): general benefit, Not a benefit
  • Glyburide (Apo-Glyburide): general benefit, Not a benefit

12 more in the class list below

Apo-Canagliflozin · DIN 02564556 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Canagliflozin · DIN 02564556 Manufacturer: Apotex Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-29 · brand APO-CANAGLIFLOZIN · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Canagliflozin: Formulary list price $0.7228/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106724 · Verify on the e-Formulary ↗ (DIN 02564556)

Source record
DIN 02564556: Apo-Canagliflozin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002055; group id 740; item number 1809; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.7228; ministry $0.7228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02564556 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106724 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Auro-Canagliflozin · DIN 02510367 · $0.7228 Invokana · DIN 02425483 · $0.7228 Jamp Canagliflozin · DIN 02543486 · $0.7228
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02564556
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Canagliflozin · DIN 02510367 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Canagliflozin · DIN 02510367 Manufacturer: Auro Pharma Inc.; listing date 2026-02-27 Health Canada: Marketed since 2026-01-02 · brand AURO-CANAGLIFLOZIN · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Canagliflozin: Formulary list price $0.7228/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99959 · Verify on the e-Formulary ↗ (DIN 02510367)

Source record
DIN 02510367: Auro-Canagliflozin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002055; group id 740; item number 1809; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.7228; ministry $0.7228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510367 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99959 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564556 · $0.7228 Invokana · DIN 02425483 · $0.7228 Jamp Canagliflozin · DIN 02543486 · $0.7228
Shortage status: resolved shortage (ended 2026-03-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510367
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invokana · DIN 02425483 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists INVOKANA (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Invokana · DIN 02425483 Manufacturer: Janssen Inc.; listing date 2015-07-29 Health Canada: Marketed since 2014-06-03 · brand INVOKANA · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 100 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.7228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91013 · Verify on the e-Formulary ↗ (DIN 02425483)

Source record
DIN 02425483: Invokana Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002055; group id 740; item number 1809; lccId None; manufacturer id JAN Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $2.8910; ministry $0.7228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02425483 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91013 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564556 · $0.7228 Auro-Canagliflozin · DIN 02510367 · $0.7228 Jamp Canagliflozin · DIN 02543486 · $0.7228
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02425483
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Canagliflozin · DIN 02543486 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Canagliflozin · DIN 02543486 Manufacturer: Jamp Pharma Corporation; listing date 2026-02-27 Health Canada: Marketed since 2026-01-02 · brand JAMP CANAGLIFLOZIN · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Canagliflozin: Formulary list price $0.7228/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103194 · Verify on the e-Formulary ↗ (DIN 02543486)

Source record
DIN 02543486: Jamp Canagliflozin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002055; group id 740; item number 1809; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.7228; ministry $0.7228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02543486 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103194 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564556 · $0.7228 Auro-Canagliflozin · DIN 02510367 · $0.7228 Invokana · DIN 02425483 · $0.7228
Shortage status: active shortage (reported 2026-03-10, estimated to end 2027-01-08, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543486
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Canagliflozin · DIN 02564564 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Canagliflozin · DIN 02564564 Manufacturer: Apotex Inc.; listing date 2026-06-30 Health Canada: Marketed since 2026-05-29 · brand APO-CANAGLIFLOZIN · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 300 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Canagliflozin: Formulary list price $0.7515/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7515 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106725 · Verify on the e-Formulary ↗ (DIN 02564564)

Source record
DIN 02564564: Apo-Canagliflozin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002056; group id 740; item number 1810; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.7515; ministry $0.7515 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02564564 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106725 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Auro-Canagliflozin · DIN 02510375 · $0.7515 Invokana · DIN 02425491 · $0.7515 Jamp Canagliflozin · DIN 02543494 · $0.7515
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02564564
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Canagliflozin · DIN 02510375 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Canagliflozin · DIN 02510375 Manufacturer: Auro Pharma Inc.; listing date 2026-02-27 Health Canada: Marketed since 2026-01-02 · brand AURO-CANAGLIFLOZIN · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 300 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Canagliflozin: Formulary list price $0.7515/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7515 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99960 · Verify on the e-Formulary ↗ (DIN 02510375)

Source record
DIN 02510375: Auro-Canagliflozin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002056; group id 740; item number 1810; lccId None; manufacturer id AUR Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.7515; ministry $0.7515 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02510375 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99960 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564564 · $0.7515 Invokana · DIN 02425491 · $0.7515 Jamp Canagliflozin · DIN 02543494 · $0.7515
Shortage status: resolved shortage (ended 2026-04-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02510375
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Invokana · DIN 02425491 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists INVOKANA (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Invokana · DIN 02425491 Manufacturer: Janssen Inc.; listing date 2015-07-29 Health Canada: Marketed since 2014-05-28 · brand INVOKANA · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 300 MG · company Janssen inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.7515 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91014 · Verify on the e-Formulary ↗ (DIN 02425491)

Source record
DIN 02425491: Invokana Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002056; group id 740; item number 1810; lccId None; manufacturer id JAN Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $3.0060; ministry $0.7515 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02425491 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91014 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564564 · $0.7515 Auro-Canagliflozin · DIN 02510375 · $0.7515 Jamp Canagliflozin · DIN 02543494 · $0.7515
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02425491
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Canagliflozin · DIN 02543494 · 300mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Canagliflozin · DIN 02543494 Manufacturer: Jamp Pharma Corporation; listing date 2026-02-27 Health Canada: Marketed since 2026-01-02 · brand JAMP CANAGLIFLOZIN · ATC A10BK02 CANAGLIFLOZIN · form Tablet · route Oral · ingredients CANAGLIFLOZIN 300 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Canagliflozin: Formulary list price $0.7515/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7515 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103195 · Verify on the e-Formulary ↗ (DIN 02543494)

Source record
DIN 02543494: Jamp Canagliflozin Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002056; group id 740; item number 1810; lccId None; manufacturer id JPC Source form: Tab; strength: 300mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.7515; ministry $0.7515 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02543494 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103195 Therapeutic Notes (formulary) Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have: . Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR . Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Canagliflozin · DIN 02564564 · $0.7515 Auro-Canagliflozin · DIN 02510375 · $0.7515 Invokana · DIN 02425491 · $0.7515
Shortage status: active shortage (reported 2026-03-10, estimated to end 2026-12-04, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543494
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLICLAZIDE, GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

GLICLAZIDE

· 19 products · General benefit (18), Listed, not a benefit (1) · strengths: 60mg, 30mg, 80mg · ER Tab, SR Tab, Tab

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

SITAGLIPTIN

· 48 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: major adverse cardiovascular events
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. SEMAGLUTIDE · Limited Use, codes 667 (2), Limited Use, codes 666 (2), Limited Use, codes 665 (3), Limited Use, codes 738 (1), Limited Use, codes 662 (1), Limited Use, codes 739 (1), Limited Use, codes 663 (1), Limited Use, codes 740 (1), Limited Use, codes 664 (1), Off-Formulary Interchangeable, not an ODB benefit (2) OZEMPIC® is indicated as an adjunct to diet, exercise, and standard of care to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease. PM: https://pdf.hres.ca/dpd_pm/00085314.PDF; date 2026-07-13; DIN 02471469; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS Monotherapy: INVOKANA® (canagliflozin) is indicated as an adjunct to diet and exercise to improve glycemic control in adult patients with type 2 diabetes mellitus for whom metformin is inappropriate due to contraindications or intolerance. Add-on combination: INVOKANA (canagliflozin) is indicated for use in adult patients with type 2 diabetes mellitus to improve glycemic control in combination with: • metformin • sulfonylurea (with or without metformin) • pioglitazone with metformin • metformin and sitagliptin • insulin (with or without metformin) when the therapy listed above, along with diet and exercise, does not provide adequate glycemic control (see 14 CLINICAL TRIALS). Add-On Combination in Patients with Established Cardiovascular Disease: INVOKANA is indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). Patients with Diabetic Nephropathy: INVOKANA is indicated as an adjunct … https://pdf.hres.ca/dpd_pm/00074895.PDF PM date: May 22, 2014 Source product: INVOKANA; DIN 02425483; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Jamp Canagliflozin · DIN 02543486 Shortage status: active shortage (reported 2026-03-10, estimated to end 2027-01-08, last updated 2026-07-29); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543486

Check this DIN again

Jamp Canagliflozin · DIN 02543494 Shortage status: active shortage (reported 2026-03-10, estimated to end 2026-12-04, last updated 2026-05-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02543494

Check this DIN again